Balance Sheet
Accounts PayablesAccumulated ExpensesCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent TaxesGoodwill & IntangiblesInventoryLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Long-Term Deferred Tax: 2023-2025

  • Zhengye Biotechnology Holding's Long-Term Deferred Tax was N/A to $2.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was $2.3 million, marking a year-over-year change of. This contributed to the annual value of $1.5 million for FY2024, which is 10.67% down from last year.
  • Per Zhengye Biotechnology Holding's latest filing, its Long-Term Deferred Tax stood at $2.3 million for Q2 2025, which was up 49.92% from $1.5 million recorded in Q4 2024.
  • In the past 5 years, Zhengye Biotechnology Holding's Long-Term Deferred Tax ranged from a high of $2.3 million in Q2 2025 and a low of $1.5 million during Q4 2024.
  • For the 3-year period, Zhengye Biotechnology Holding's Long-Term Deferred Tax averaged around $1.8 million, with its median value being $1.7 million (2023).
  • Data for Zhengye Biotechnology Holding's Long-Term Deferred Tax shows a maximum YoY declined of 8.99% (in 2024) over the last 5 years.
  • Over the past 3 years, Zhengye Biotechnology Holding's Long-Term Deferred Tax (Quarterly) stood at $1.7 million in 2023, then decreased by 8.99% to $1.5 million in 2024, then reached $2.3 million in 2025.
  • Its Long-Term Deferred Tax was $2.3 million in Q2 2025, compared to $1.5 million in Q4 2024 and $1.7 million in Q4 2023.